Table 1:
Demographic and clinical characteristics of the study participants.
| Characteristic | N=128 (%) |
|---|---|
| Age (years) | 47.8 (range: 19–85) |
| Female sex at birth | 57 (44.5) |
| Race | |
| American Indian or Alaska Native | 4 (3.1) |
| Asian | 15 (11.7) |
| Black or African American | 7 (5.5) |
| Native Hawaiian or Other Pacific Islander | 3 (2.3) |
| White | 81 (63.4) |
| Declined | 20 (15.6) |
| Latinx Ethnicity | 33 (25.8) |
| Medical Comorbidities | |
| Autoimmune disease | 9 (7.0) |
| Active cancer | 3 (2.3) |
| Diabetes | 17 (13.3) |
| HIV | 18 (14.1) |
| Heart disease | 3 (2.3) |
| Hypertension | 29 (22.7) |
| Lung disease | 21 (16.4) |
| Kidney disease | 2 (1.6) |
| Obesity (BMI ≥ 30) | 38 (29.7) |
| Clinical Manifestations of COVID-19 | |
| Asymptomatic | 7 (5.5) |
| Symptomatic | 121 (94.5) |
| Fever | 86 (70.5) |
| Chills | 75 (61.5) |
| Fatigue | 110 (90.2) |
| Cough | 89 (73.0) |
| Shortness of breath | 77 (63.1) |
| Rhinorrhea | 58 (47.5) |
| Sore throat | 56 (45.9) |
| Myalgias | 84 (68.9) |
| Nausea | 36 (29.5) |
| Vomiting | 12 (9.8) |
| Diarrhea | 50 (41.0) |
| Anosmia or dysgeusia | 82 (67.2) |
| Headache | 77 (63.1) |
| Hospitalized | 31 (24.2) |
| Required supplemental oxygen | 26 (83.9) |
| Required ICU admission | 13 (41.9) |
| Required mechanical ventilation | 4 (12.9) |
| Numbers of symptoms reported | |
| 1 to 3 | 13 (10.2%) |
| 4 to 6 | 34 (26.6%) |
| 7 to 9 | 47 (36.7%) |
| 10 to 13 | 27 (21.1%) |
| Enrollment and follow-up | |
| Baseline visit, days since onset (median) | 63 (range: 22–157) |
| Follow-up time, days since onset (median) | 110 (range: 22–157) |
| Time points contributed (median) | 2 (range: 1–4) |